MarzAA

August 20, 2018August 20, 2018

Phase 2/3 Clinical Trial of MarzAA Shows Promise in Hemophilia Treatment

News

Catalyst Biosciences announced positive interim results from a Phase 2/3 clinical trial (NCT03407651) of the Factor VIIa variant marzeptacog alfa (activated) (MarzAA) in the preventative treatment of patients with ... Read more

January 8, 2018

Catalyst Biosciences Starts Phase 2/3 Trial of Therapy to Prevent Hemophilia Bleeding Episodes

News

Catalyst Biosciences has begun enrolling patients in a Phase 2/3 clinical trial of marzeptacog alfa (activated) as a preventive treatment for hemophilia A or B. Some patients develop immune responses — ... Read more

Pin It on Pinterest